← Back to patent-cliff list
CAS 1798323-79-1
(3S)-1-Benzyl-2,6-dioxopiperidin-3-yl chloroacetate
Codes: (IIIb)461018-5-a
Application context (from source-drug indications)
Waldenström macroglobulinaemiaIbrutinibChronic lymphocytic leukaemiaIbrutinibMantle cell lymphomaIbrutinibGraft-versus-host diseaseIbrutinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ibrutinib | Tier A — Act now | 2027 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(2S)-5-oxooxolane-2-carboxylic acid→(2S)-5-(Benzylamino)-2-hydroxy-5-oxopentanoic acid→(3S)-1-Benzyl-2,6-dioxopiperidin-3-yl acetate→(3S)-1-Benzyl-2,6-dioxopiperidin-3-yl chloroacetate→(3S)-1-Benzyl-2,6-dioxopiperidin-3-yl trifluoroacetate→(3S)-1-Benzylpiperidin-3-ol→(3S)-Piperidin-3-ol acetate→(3S)-1-(tert-Butoxycarbonyl)-3-hydroxypiperidine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.